some fatal. Tell your doctor if you have liver problems and
contact your doctor immediately if you develop symptoms such as jaundice
(yellow skin and eyes), dark brown urine, right-sided abdominal pain,
fever, or severe fatigue. Blood disorders have been reported, some fatal.
Tell your doctor if you develop possible signs of blood disorders such as
persistent fever, bruising, bleeding, or paleness while taking REMICADE.
Nervous system disorders have also been reported. Tell your doctor if you
have or have had a disease that affects the nervous system, or if you
experience any numbness, weakness, tingling, visual disturbances or
seizures while taking REMICADE.
Allergic reactions, some severe have been reported during or after
infusions with REMICADE. Signs of an allergic reaction include hives,
difficulty breathing, chest pain, high or low blood pressure, swelling of
face and hands, and fever or chills. Tell your doctor if you have
experienced a severe allergic reaction. The most common side effects of
REMICADE are: respiratory infections, such as sinus infections and sore
throat, headache, rash, coughing, and stomach pain.
Please read important information about REMICADE, including full U.S.
prescribing information and Medication Guide, at http://www.REMICADE.com. For
complete EU prescribing information, please visit http://www.emea.eu.int.
Centocor is harnessing the power of world-leading research and
biomanufacturing to deliver innovative biomedicines that transform
patients' lives. Centocor has already brought innovation to the treatment
of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic
arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis. The
world leader in monoclonal antibody production and technology, Centocor has
brought critical biologic therapies to patients suffering from
Page: 1 2 3 4 5 6 7 8 9 10 11 12 Related biology technology :1
|SOURCE Centocor, Inc.|
Copyright©2007 PR Newswire.
All rights reserved
. BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy2
. Haemonetics Becomes Preferred Provider of Plasma Collection Products to Octapharma Europe3
. Prof. Michel Klein Becomes Chief Scientific Officer at AMVAC4
. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis5
. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award6
. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend7
. Genmab Announces 2007 First Half Year Results8
. Pharsight Achieves First License Sale for Public-Source Database9
. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments10
. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials11
. China Medical Technologies Reports First Quarter Financial Results